Trial Profile
N7: evaluation of maximal chemotherapy dose intensity plus monoclonal antibody 3F8 in the treatment of neuroblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Antineoplastics; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Filgrastim; Vincristine
- Indications Neuroblastoma
- Focus Therapeutic Use
- 17 Dec 2009 Actual end date (Sep 2004) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Sep 2005 New trial record.